COMPLETED

Continuous vs. Intermittent Infusion Vancomycin

Conditions

Vancomycin Infusion Adverse Effect Acute Kidney Injury

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Hospitalized adult participants prescribed vancomycin by their treating physician will be randomized to receive vancomycin via continuous or intermittent infusion and measures of kidney function and injury will be collected.

Official Title

A Randomized Clinical Trial of Continuous vs. Intermittent Infusion Vancomycin: Effects on Measured GFR and Kidney Injury Biomarkers

Quick Facts

Study Start:2023-05-22

Study Completion:2025-06-15

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT05823116

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* ≥ 18 years of age * Hospitalized at University of Kentucky on a medical service (internal medicine or medical intensive care) * Prescribed ≥ 2 doses of vancomycin per treating physician * Be able to provide written, informed consent, or have a legally authorized representative (LAR) responsible for their care able to provide written, informed consent.	* Chronic kidney disease (documented or prior to admission estimated GFR (eGFR) \<60 ml/min/1.73m2 using non-race-based creatinine GFR equation) * End stage kidney disease * Stage 1 or higher AKI per Kidney Disease: Improving Global Outcomes (KDIGO) classification (serum creatinine increase ≥ 0.3 mg/dl or 1.5-1.9 times baseline; urine output \< 0.5 ml/kg/hr for 6-12 hours) * Greater than 2 doses of vancomycin within the last 72 hours * Allergy to iohexol * Uroepithelial tumors * Pregnancy * Prisoner

Inclusion Criteria

Exclusion Criteria

* ≥ 18 years of age
* Hospitalized at University of Kentucky on a medical service (internal medicine or medical intensive care)
* Prescribed ≥ 2 doses of vancomycin per treating physician
* Be able to provide written, informed consent, or have a legally authorized representative (LAR) responsible for their care able to provide written, informed consent.

* Chronic kidney disease (documented or prior to admission estimated GFR (eGFR) \<60 ml/min/1.73m2 using non-race-based creatinine GFR equation)
* End stage kidney disease
* Stage 1 or higher AKI per Kidney Disease: Improving Global Outcomes (KDIGO) classification (serum creatinine increase ≥ 0.3 mg/dl or 1.5-1.9 times baseline; urine output \< 0.5 ml/kg/hr for 6-12 hours)
* Greater than 2 doses of vancomycin within the last 72 hours
* Allergy to iohexol
* Uroepithelial tumors
* Pregnancy
* Prisoner

Contacts and Locations

Principal Investigator

Aaron M Cook, PharmD

PRINCIPAL_INVESTIGATOR

University of Kentucky

Study Locations (Sites)

University of Kentucky

Lexington, Kentucky, 40506

United States

Collaborators and Investigators

Sponsor: Aaron Cook

Aaron M Cook, PharmD, PRINCIPAL_INVESTIGATOR, University of Kentucky

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-22

Study Completion Date2025-06-15

Study Record Updates

Study Start Date2023-05-22

Study Completion Date2025-06-15

Terms related to this study

Keywords Provided by Researchers

Infusion
Adverse Effect
Acute Kidney Injury

Additional Relevant MeSH Terms

Vancomycin